OncoC4's Bispecific Antibody Shows 33% Objective Response Rate in PD-(L)1-Resistant Lung Cancer

OncoC4 has reported encouraging Phase 1/2 clinical data for its investigational PD-1/VEGF bispecific antibody, cesalatamig (AI-081), as a monotherapy for patients with PD-(L)1-resistant or refractory non-small cell lung cancer (NSCLC). The data, presented at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, showed a 33% investigator-assessed objective response rate and a 90% disease control rate at the 10 mg/kg dose.